Cassava Sciences Inc
Cassava Sciences Inc is a biopharmaceutical company focused on the development of treatments for Alzheimer's and other neurodegenerative diseases.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Cassava Sciences' stock with a target price of $75, indicating potential growth.
Financial Health
Cassava Sciences is showing solid cash flow and book value, indicating a stable financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SAVA
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical readouts matter
Upcoming trial results and regulatory updates can rapidly change valuation, though outcomes can be binary and unpredictable.
Research‑driven upside
If clinical data are positive, the company could see substantial appreciation; investors should weigh potential reward against high risk.
Scientific scrutiny relevant
Peer‑review, regulatory commentary and independent analysis are important to assess credibility, while remembering biotech outcomes can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
